NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 08/01/2024 at 12:30, 1 year 7 months ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
NanoViricides, Inc., reports on independent research highlighting NV-387's broad-spectrum action in viral therapy, potentially revolutionizing antiviral treatment strategies

NV-387 NanoViricides Inc. Antiviral Nanomedicines Broad-spectrum Action Viral Therapy
BRIEF

published on 07/24/2024 at 12:35, 1 year 8 months ago

NanoViricides Highlights NV-387's Potential Against COVID-19

COVID-19 NanoViricides NV-387 Clinical Trials Antiviral
BRIEF

published on 07/24/2024 at 12:35, 1 year 8 months ago

Les nanoviricides mettent en évidence le potentiel du NV-387 contre le COVID-19

NanoViricides NV-387 Essais Cliniques COVID 19 Antiviral
PRESS RELEASE

published on 07/24/2024 at 12:30, 1 year 8 months ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
NanoViricides, Inc. showcases strong safety and effectiveness of lead drug NV-387 against coronaviruses, potentially filling the gap in COVID treatments. Seeking collaborations for regulatory approvals

NanoViricides NV-387 Drug Development Coronaviruses COVID Treatments
BRIEF

published on 07/11/2024 at 12:35, 1 year 8 months ago

NanoViricides Plans Next Phase of Clinical Trials for Broad-Spectrum Antiviral NV-387

NanoViricides NV-387 Clinical Trials Antiviral Drug Broad-spectrum
BRIEF

published on 07/11/2024 at 12:35, 1 year 8 months ago

NanoViricides prévoit la prochaine phase d'essais cliniques pour l'antiviral à large spectre NV-387

NanoViricides NV-387 Essais Cliniques Médicament Antiviral Large Spectre
PRESS RELEASE

published on 07/11/2024 at 12:30, 1 year 8 months ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
NanoViricides, Inc. discusses development program for antiviral drug NV-387 effective against various respiratory infections, advancing towards human clinical trials

NV-387 Clinical Trials Respiratory Infections NanoViricides Inc. Antiviral Drug
BRIEF

published on 07/01/2024 at 12:35, 1 year 8 months ago

NanoViricides Advances Broad-Spectrum Antiviral Drug Development

NanoViricides NV-387 Clinical Trials Antiviral RSV
BRIEF

published on 07/01/2024 at 12:35, 1 year 8 months ago

Les nanoviricides font progresser le développement de médicaments antiviraux à large spectre

NanoViricides NV-387 Essais Cliniques Antiviral VRS
PRESS RELEASE

published on 07/01/2024 at 12:30, 1 year 8 months ago

NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides, Inc. elaborates on its lead broad-spectrum antiviral drug candidate NV-387, poised to revolutionize viral disease treatment. Plans include Phase II studies for RSV and market expansion

NV-387 NanoViricides Inc. Antiviral Drug Viral Diseases Phase II Studies

Published on 03/26/2026 at 16:20, 1 hour 33 minutes ago

ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 14:05, 3 hours 48 minutes ago

SouthGobi Announces Profit Warning
Published on 03/26/2026 at 13:00, 4 hours 53 minutes ago

Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 4 hours 53 minutes ago

GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 4 hours 54 minutes ago

Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance

View all ACCESSWIRE

Published on 03/26/2026 at 17:45, 8 minutes ago

CTS EVENTIM exceeds EUR 3 billion in revenue for the first time, sustaining profitable growth
Published on 03/26/2026 at 17:20, 32 minutes ago

EQS-Adhoc: Leifheit Aktiengesellschaft: Board of Management and Supervisory Board propose to the Annual General Meeting a capital increase from the company’s own funds, followed by an ordinary capital reduction
Published on 03/26/2026 at 17:19, 33 minutes ago

Haier Smart Home Reports Full-Year 2025 Results: Global Revenue Surpasses RMB 300 Billion for the First Time; Net Profit Reaches a Record Highs
Published on 03/26/2026 at 17:13, 39 minutes ago

Custodian Property Income REIT plc: Share Buyback
Published on 03/26/2026 at 17:03, 49 minutes ago

RM plc: 2025 Annual Report and Financial Statements and 2026 Annual General Meeting

View all EQS

Published on 03/26/2026 at 17:45, 8 minutes ago

Cegedim : poursuite de l’amélioration de la rentabilité
Published on 03/26/2026 at 17:45, 8 minutes ago

Cegedim: profitability continues to improve
Published on 03/26/2026 at 08:57, 8 hours 55 minutes ago

Communiqué Edenred
Published on 03/26/2026 at 08:57, 8 hours 55 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 10 hours 23 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY

View all LES ECHOS COMFI WIRE

News